Spyre Therapeutics (NASDAQ:SYRE) Shares Up 6.1%

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) shot up 6.1% on Monday . The company traded as high as $35.79 and last traded at $35.61. 30,426 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 444,849 shares. The stock had previously closed at $33.56.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wells Fargo & Company upgraded Spyre Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $12.00 to $35.00 in a research note on Friday, March 1st. Stifel Nicolaus boosted their target price on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, March 26th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $39.20.

Spyre Therapeutics Stock Up 4.0 %

The company's 50-day moving average price is $35.15. The company has a market capitalization of $1.26 billion, a PE ratio of -0.46 and a beta of 2.88.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($1.80). As a group, research analysts predict that Spyre Therapeutics, Inc. will post -2.36 EPS for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).